OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

CEO exercised or converted 0 CHE derivative securities | OQRO

Home
Insider trades
Chemed Corp.
CEO exercised or converted 0 CHE derivative securities

Insider trades

Insider trade

CEO exercised or converted 0 CHE derivative securities

Traded Feb 13, 2026 · Filed Feb 17, 2026

CHEChemed Corp.CHE

0
Shares · @ $469.56

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 13, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 17, 2026

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001193125-26-054514

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Feb 17, 2026, 8:58 PM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CHEMED CORP

Issuer CIK

19584

Ticker

CHE

Reporting person

Joel L Wherley

Relationship

Officer

Officer title

CEO - Vitas Healthcare

Security

Capital Stock

Table

Non-derivative (Table I)

Transaction date

Feb 13, 2026

Transaction code

Shares / units

Price per share

$469.56

Acquired / disposed

Acquired (A)

Shares owned after

932

Ownership form

Direct

Amendment

Footnotes from the filing

The number of PSUs that vested was based on the Company's achieving relative total shareholder returns for the period January 1, 2023 through December 31, 2025, compared to a defined peer group of companies. The Company's performance ranked in the 7th percentile of that group, yielding an award of 0%; including the reinvestment of dividends paid during such period, the award is 0% of target.